News & Updates

Show Multimedia Only

Determinants of semaglutide initiation in obesity

30 Jan 2025

In people with obesity but without diabetes, starting semaglutide treatment appears to be influenced by sociodemographic, health care, and clinical factors, according to a retrospective observational cohort study.

Determinants of semaglutide initiation in obesity

30 Jan 2025

Empagliflozin, dapagliflozin in a draw for renoprotection in T2D

29 Jan 2025 by

Long-term kidney outcomes in type 2 diabetes (T2D) are similar between empagliflozin- and dapagliflozin-treated patients, aligning with current clinical practice guidelines that do not favour one SGLT2 inhibitor over the other, according to a study.

Empagliflozin, dapagliflozin in a draw for renoprotection in T2D

29 Jan 2025

GLP-1 RAs reduce BP in overweight, obese patients

29 Jan 2025

The use of glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly lowers blood pressure (BP) in obese or overweight patients, according to a study. This beneficial effect persists across diabetic status, duration of treatment, and route of administration.

GLP-1 RAs reduce BP in overweight, obese patients

29 Jan 2025

One basal insulin noninferior to another in type 2 diabetes

29 Jan 2025

In the management of type 2 diabetes (T2D) in adults who are naïve to insulin, once-weekly efsitora alfa compares favourably with once-daily degludec in terms of lowering glycated haemoglobin levels, according to an open-label phase III study.

One basal insulin noninferior to another in type 2 diabetes

29 Jan 2025

Novel injectable paste-based treatment promotes diabetic foot wound closure

27 Jan 2025 by

Micronized injectable human-derived acellular dermal matrices (ADM) may improve the healing of diabetic foot wounds, according to real-world data from Singapore.

Novel injectable paste-based treatment promotes diabetic foot wound closure

27 Jan 2025

Sit less, move more, as CV risk remains even with exercise

27 Jan 2025 by

For individuals who sit for the most part of their day, engaging in light or moderate physical activity may be insufficient to cancel out the cardiovascular (CV) risks tied to a sedentary lifestyle, a study suggests.

Sit less, move more, as CV risk remains even with exercise

27 Jan 2025

Biological mechanisms link dietary quality to T2D risk

24 Jan 2025

A recent study has found novel biological pathways that show the association of certain dietary patterns with the development of type 2 diabetes (T2D).

Biological mechanisms link dietary quality to T2D risk

24 Jan 2025

Remote weight management programme benefits individuals with overweight, long COVID

24 Jan 2025 by

A remotely delivered structured weight management programme appears effective and safe in reducing symptoms that matter most among individuals with long COVID (LC) and overweight, findings from the wait-list-controlled open-label ReDIRECT trial suggest.

Remote weight management programme benefits individuals with overweight, long COVID

24 Jan 2025

Combination biomarkers foretell long-term cardiovascular risk in women

22 Jan 2025

A single combined measure of high-sensitivity C-reactive protein (CRP), low-density lipoprotein (LDL) cholesterol, and lipoprotein(a) levels may predict the incidence of cardiovascular events over a 30-year period, as shown in a study.

Combination biomarkers foretell long-term cardiovascular risk in women

22 Jan 2025

Early SGLT2i initiation stalls CKD progression, may delay dialysis

20 Jan 2025 by

Empagliflozin’s recently approved chronic kidney disease (CKD) indication expands the spectrum of patients with cardio-renal-metabolic (CRM) conditions who may benefit from treatment. At the 26^th Diabetes and Cardiovascular Risk Factors – East Meets West Symposium, Dr Ted Wu, Director of the Diabetes Centre, Royal Prince Alfred Hospital in Sydney, Australia, and Honorary Professor, Shijiazhuang Diabetes Hospital, Hebei, China, highlighted empagliflozin’s benefits in CKD, type 2 diabetes (T2D) and heart failure (HF), and discussed how early initiation of empagliflozin may stall CKD progression and delay dialysis.

Early SGLT2i initiation stalls CKD progression, may delay dialysis

20 Jan 2025

News & Updates

Filter by Specialty:

Specialty:

Determinants of semaglutide initiation in obesity

Determinants of semaglutide initiation in obesity

Empagliflozin, dapagliflozin in a draw for renoprotection in T2D

Empagliflozin, dapagliflozin in a draw for renoprotection in T2D

GLP-1 RAs reduce BP in overweight, obese patients

GLP-1 RAs reduce BP in overweight, obese patients

One basal insulin noninferior to another in type 2 diabetes

One basal insulin noninferior to another in type 2 diabetes

Novel injectable paste-based treatment promotes diabetic foot wound closure

Novel injectable paste-based treatment promotes diabetic foot wound closure

Sit less, move more, as CV risk remains even with exercise

Sit less, move more, as CV risk remains even with exercise

Biological mechanisms link dietary quality to T2D risk

Biological mechanisms link dietary quality to T2D risk

Remote weight management programme benefits individuals with overweight, long COVID

Remote weight management programme benefits individuals with overweight, long COVID

Combination biomarkers foretell long-term cardiovascular risk in women

Combination biomarkers foretell long-term cardiovascular risk in women

Early SGLT2i initiation stalls CKD progression, may delay dialysis

Early SGLT2i initiation stalls CKD progression, may delay dialysis